Maintenance Stack On Top of Semaglutide — PsA at Baseline

Before talking additions, credit the baseline. Semaglutide is not a neutral presence in this strategy — it is the peptide with the strongest direct human evidence for the indication in question.

• Anti-inflammatory meta-analysis — 13 RCTs, n=26,131: CRP index SMD −0.56 (95% CI −0.69 to −0.43) vs placebo, robust across T2DM and obesity subgroups and oral/subcutaneous routes (doi:10.3389/fcvm.2024.1379189).
• Direct psoriasis RCT — 12 weeks, n=31 obese T2DM patients: PASI 21 → 10 (p=0.002), DLQI 14 → 4, significant IL-6 and CRP reductions (doi:10.3390/biom15010046).
• Epicardial-fat + psoriasis severity case series (doi:10.1530/EDM-23-0017).
• SIB trial (NCT04979130) — RCT testing whether semaglutide itself tightens intestinal permeability and lowers hs-CRP, IL-6, TNF, IL-1, IL-8, LBP, and fecal calprotectin. Design paper: doi:10.1177/20420188231207348. Relevant because this may partially subsume what a zonulin antagonist (larazotide) would add.

Clinical Strength: A for anti-inflammatory / psoriasis.

Implication: semaglutide is already carrying real anti-inflammatory load. Any added peptide must show marginal benefit over that baseline — a higher bar than most peptide-market narratives acknowledge. Do not double-count the baseline against the stack.

Meaningful human evidence AND meaningful community N.

After applying the "Signal ≠ Science" filter, exactly one candidate besides the semaglutide baseline lands in this tier.

Tesamorelin

Stabilized GHRH(1–44) analog, FDA-approved as Egrifta for HIV-associated lipodystrophy. In HIV-NAFLD transcriptomics it has been shown to downregulate hepatic inflammation and fibrosis gene sets in humans.

• Clinical Strength: B. Tier B human evidence for anti-inflammatory effects via HIV-NAFLD RCTs (doi:10.1172/jci.insight.140134, doi:10.1038/s41598-021-89966-y). No direct PsA trial exists — hepatic inflammation is not joint inflammation, even if both sit under systemic low-grade inflammation.
• Community Sentiment: B (n=362 posts / 94 unique dosers in our corpus; n=13 sema co-authors). Keyword-sentiment ratio 2.0 pos:neg. Discussed more in metabolic/visceral-fat framing than inflammation framing; sleep co-mention (n=21 posts / 15 threads) is real but secondary.
• Mechanism: GHRH analog → pulsatile GH → IGF-1 rise → anti-inflammatory gene-set modulation (documented in liver) + enhanced slow-wave sleep.
• Why this matters for this use case: GH-driven slow-wave sleep directly addresses the sleep goal. The hepatic anti-inflammatory gene-set shift is the closest documented systemic-inflammation signal in humans — extrapolating from liver to synovium is speculative, but the low-grade systemic inflammation axis is plausibly shared. IGF-1-driven tendon/cartilage support is adjacent to enthesitis biology in PsA.
• Most Discussed Protocols: 1 mg daily subcutaneous is modal (n=11 dosing rows). Also 2 mg daily (n=7), 2 mg 5x/week (n=1). FDA-label dose for lipodystrophy is 2 mg daily.
• Monitoring labs (mandatory): IGF-1 at baseline, 6–8 weeks after start, then every 3 months — target mid-normal range for age, not elevated. Fasting glucose and HbA1c (GH induces insulin resistance; semaglutide partially offsets). hs-CRP/ESR for the thing you are actually trying to preserve.
• When to stop: IGF-1 above age-adjusted upper limit of normal; rising HbA1c; fluid retention, carpal-tunnel symptoms, new arthralgia (can mimic PsA flare); any confirmed PsA flare.

Honest framing up front. The five candidates below have massive community discussion and plausible mechanism, but zero or near-zero human RCT evidence for inflammation/autoimmune/PsA indications. Community Sentiment grades are legitimately high because N is high and tone is positive. Clinical Strength grades are low because the human trial base is not there. Choosing any of these is a bet on mechanism and community signal, not on clinical evidence.

Two corpus caveats: (1) this corpus is GLP-1 weighted, so peptide evidence here is a floor, not a ceiling — external PubMed has more on BPC-157, TB-500, KPV, MOTS-c than shows here; (2) all five are Research Compounds, not FDA-approved for any relevant indication, and supply chain quality (third-party CoA, heavy-metals, identity-vs-purity testing) is the real-world risk control.

BPC-157

• Clinical Strength: C. 56 corpus hits, zero clinical trials — 8 reviews, 7 basic science, 1 other. 2025 narrative review flags safety gaps (doi:10.1007/s12178-025-09990-7). Pleiotropic patent/mechanism review (doi:10.3390/ph18020185).
• Community Sentiment: A (n=380 posts / 107 unique dosers; n=23 sema co-authors — the highest of any peptide on this shortlist). Sentiment ratio 2.2 pos:neg. The "Wolverine stack" (BPC-157 + TB-500 ± GHK-Cu) is the dominant recovery pattern among semaglutide users who add anything.
• Mechanism: pentadecapeptide from gastric juice; VEGF-pathway angiogenesis, NO modulation, tendon/ligament/gut mucosal support. Theoretical VEGF concern with active or occult malignancy (no human data confirms or refutes).
• Why this matters for this use case: Gut-mucosal support overlaps with the SIB-trial hypothesis that semaglutide itself tightens gut barrier — BPC-157 may be additive or redundant, unknown which. Tendon/ligament healing is directly relevant to PsA enthesitis. VEGF/angiogenesis is neutral-to-helpful at healthy baseline but worth flagging long-term given synovial pannus biology in PsA.
• Most Discussed Protocols: 500 mcg daily SC modal. Also 250 mcg daily, 1 mg daily, "10 units daily."
• Monitoring: hs-CRP, ESR, CBC, CMP baseline + every 3 months. No BPC-157-specific surveillance panel exists.
• When to stop: any new or growing mass; any PsA flare; escalating injection-site reactions.

TB-500 (Thymosin β-4 fragment)

• Clinical Strength: C for PsA indication; B for general tissue-repair human data via endogenous Tβ4. Includes 2 clinical trials: Sjögren's syndrome (doi:10.1186/s13075-016-1134-7) and OSA serum Tβ4 (doi:10.1002/jcla.21930). Theoretical cancer-metastasis concern via actin polymerization; observational thyroid-cancer association (doi:10.1369/00221554221138370).
• Community Sentiment: A (n=347 posts / 59 unique dosers; n=14 sema co-authors). Sentiment ratio 2.3 pos:neg. Almost always paired with BPC-157 in dosing rows.
• Mechanism: G-actin sequestering peptide; wound healing, anti-fibrotic, anti-inflammatory.
• Why this matters for this use case: Anti-fibrotic + anti-inflammatory activity is the most mechanistically on-point for holding a baseline after stopping a DMARD/biologic. Direct tendon-healing utility for PsA enthesitis risk.
• Most Discussed Protocols: 1 mg daily SC modal; also 1.25 mg daily, 10 units daily, 1 mg 2x/week.
• Monitoring: hs-CRP, ESR, CBC, CMP baseline + quarterly. Relative contraindication with active or recent malignancy.
• When to stop: same as BPC-157. Community pattern favors defined 6–12 week repair cycles over continuous dosing.

GHK-Cu

• Clinical Strength: C for injectable systemic use (0 clinical trials in corpus; rat UC/colitis doi:10.3389/fphar.2025.1551843, rat silicosis doi:10.1016/j.redox.2024.103237, mechanism review doi:10.1155/2015/648108). B for topical via decades of cosmeceutical human use.
• Community Sentiment: A (n=635 posts / 101 unique dosers; n=18 sema co-authors). Sentiment ratio 2.0 pos:neg. Caveat: corpus volume is heavily skin/hair cosmetic — do not read the 635 post count as PsA-relevant signal.
• Mechanism: endogenous copper-binding tripeptide; Nrf2 pathway; ~4,000-gene expression modulation; skin regeneration.
• Why this matters for this use case: Nrf2 activation is a legitimate systemic anti-oxidative axis, but the gene-modulation evidence is skin/regeneration-weighted — the jump to synovial joint inflammation is speculative. More directly relevant to psoriasis skin plaques than to the arthritis axis.
• Most Discussed Protocols: 2 mg daily SC dominant for injectable; topical preparations are separate and broadly available.
• Monitoring: serum copper + ceruloplasmin baseline and every 6 months if chronic injectable. Copper overload is the specific chronic-use concern. Topical use essentially no lab surveillance.
• When to stop: elevated copper/ceruloplasmin, neurologic symptoms, GI symptoms.

MOTS-c

• Clinical Strength: C. 86 corpus hits, 34 with inflammation overlap; 7 clinical trials + 1 MA — highest clinical-trial density in this corpus — but all on endogenous circulating MOTS-c as a biomarker, not on exogenous injection. Animal autoimmune-diabetes prevention data (doi:10.3390/ijms19061800).
• Community Sentiment: A (n=580 posts / 83 unique dosers; n=15 sema co-authors). Sentiment ratio 2.1 pos:neg.
• Mechanism: mitochondrial-derived 16-aa peptide; AMPK activation; metabolic-inflammation axis (mechanistically complementary to semaglutide).
• Why this matters for this use case: AMPK activation overlaps with semaglutide's own metabolic-inflammation axis, so the benefit here could be redundant rather than additive. The mitochondrial-function angle is the one distinct mechanistic lane, but unproven in humans for PsA or joint inflammation.
• Most Discussed Protocols: 5 mg 3x/week SC dominant; also 5 mg weekly, 10 mg weekly. Only peptide in this shortlist where weekly dosing outpaces daily.
• Monitoring: hs-CRP, ESR, CBC, CMP, fasting glucose baseline + quarterly.
• When to stop: persistent GI symptoms, unexplained fatigue, any PsA flare.

KPV (Lys-Pro-Val, α-MSH 11–13)

• Clinical Strength: D in this corpus; B for the adjacent melanocortin pathway via the afamelanotide/Scenesse precedent. Zero direct corpus hits. External literature: mouse colitis only. Melanocortin-pathway review in corpus (doi:10.3390/diseases13090305).
• Community Sentiment: B (n=157 posts / 26 unique dosers corpus-wide; n=3 sema co-authors; only n=1 post in the PsA/autoimmune-tagged subcorpus). Community N for this specific indication is small — be honest about it.
• Mechanism: C-terminal tripeptide of α-MSH; melanocortin pathway; reduces NF-κB, IL-1β, TNF-α. Studied orally for UC.
• Why this matters for this use case: NF-κB / IL-1β / TNF-α are three of the core cytokines driving PsA synovitis — mechanism-for-indication match is the cleanest in the whole stack. The catch is only that human evidence exists for GI use (UC), not joint disease.
• Most Discussed Protocols: 300–500 mcg daily SC or oral.
• Monitoring: hs-CRP, ESR, CBC, CMP; track pigmentation anecdotally.
• When to stop: any pigmentation change, PsA flare, GI issues.

Separated from the core stack because risk profile, monitoring, and evidence structure are different. The sleep pick carries mandatory IGF-1 surveillance; the core anti-inflammatory candidates do not.

Ipamorelin + CJC-1295 (mod-GRF 1-29)

• Clinical Strength: C for SWS architecture / D for direct PsA. GHRH and ghrelin-agonist class effects on slow-wave sleep are documented in small human studies outside this corpus; the specific combo has no direct human RCT here. GH-secretagogue safety review (doi:10.1016/j.sxmr.2017.02.004).
• Community Sentiment: B (ipamorelin n=252 posts / 91 unique dosers; CJC-1295 n=75 / 46; combined stack pattern seen in n=9+ dosing rows). In the sleep-tagged subcorpus: ipamorelin n=23 posts / 19 threads, CJC-1295 n=9 / 9.
• Mechanism: ipamorelin = selective GHSR (ghrelin receptor) agonist → pulsatile GH without significant cortisol/prolactin rise. CJC-1295 (mod-GRF 1-29) = GHRH analog → amplifies/prolongs GH pulses. Combined: physiologic GH pulses → enhanced slow-wave sleep (GH secretion is tightly coupled to SWS) + IGF-1 rise.
• Why this matters for this use case: GH-pulse-driven slow-wave sleep is the specific sleep architecture most disrupted by chronic inflammation and aging. If tesamorelin isn't used, this is the cleanest physiologic lever for the sleep goal, and the IGF-1 rise is tendon/cartilage-supportive.
• Why this and not MK-677: MK-677 is oral, long half-life, causes water retention, appetite surge, and prolactin rise. A corpus case report documents gynecomastia and hypogonadism in a patient taking an OTC supplement contaminated with MK-677 (doi:10.1210/jcemcr/luae148). Pulsatile SC ipa+CJC is the cleaner mechanism and cleaner safety profile for SWS.
• Most Discussed Protocols: ipamorelin 200–250 mcg + CJC-1295 200 mcg, SC pre-bed (to mirror the physiologic nocturnal GH pulse). Modal pattern is daily or 5x/week.
• Monitoring labs: IGF-1 baseline, 6–8 weeks after start, then every 3 months — target mid-normal range for age. Fasting glucose / HbA1c. Consider prolactin if gynecomastia or libido changes appear.
• When to stop: IGF-1 above age-adjusted upper limit of normal; fluid retention, carpal-tunnel symptoms, joint aches (can mimic PsA flare); rising fasting glucose; any PsA flare.
• Interaction with tesamorelin: tesamorelin in §3 provides the same GHRH-class SWS benefit and has stronger human anti-inflammatory evidence. If tesamorelin is already running, it likely subsumes the ipa+CJC sleep rationale — running both simultaneously is a higher IGF-1-pressure stack and not commonly reported in the dosing data.

These are affirmative no's, each for a specific load-bearing reason. They are not ranked.

LL-37 (cathelicidin) — hard avoid

LL-37 is a causal autoantigen in psoriasis. T cells from psoriasis patients directly target LL-37 (Lande et al. 2014 Nat Commun, foundational). Exogenous LL-37 could directly provoke a psoriasis/PsA flare. This is mechanism-level contraindication, not a monitoring argument. Corpus presence: 6 posts / 5 threads, 0 with inflammation overlap — community does not meaningfully discuss it, consistent with the science. Remove from stack consideration.

Thymosin α-1 (TA-1, thymalfasin) — hard avoid for this user

TA-1 is immune-UP, not down. It enhances T-cell maturation, NK activity, IFN-γ, and shifts Th1/Th17 balance. Approved in some countries as an antiviral adjunct and sepsis adjunct. In PsA — a Th17-driven disease — the plausible flare risk outweighs any anti-inflammatory case. Some Chinese psoriasis trials show improvement via immune rebalancing, but response variance is high and mechanism cuts both ways. Corpus PsA co-mention is small (n=3 posts / 3 threads). Do not add TA-1 to a PsA maintenance stack.

Larazotide (AT-1001) — defer, don't include

Mechanistically clean (zonulin antagonist → tightens intestinal tight junctions → reduces leaky-gut-driven immune activation), B-tier celiac RCT evidence. But the SIB trial (NCT04979130, doi:10.1177/20420188231207348) is actively testing whether semaglutide itself closes the permeability loop — measuring hs-CRP, IL-6, TNF, IL-1, IL-8, LBP, fecal calprotectin. If SIB reads out positive, semaglutide may already be doing what larazotide would add. Wait for SIB readout before considering larazotide as an add-on.

MK-677 (ibutamoren) — don't substitute for ipa+CJC

Oral GH secretagogue. Long half-life, water retention, appetite surge, prolactin elevation. Corpus case report: OTC supplement contaminated with MK-677 caused gynecomastia and hypogonadism (doi:10.1210/jcemcr/luae148) — cautionary both for the drug and the supply chain. Pulsatile SC ipa+CJC is the cleaner SWS option.

Anything that redundantly spikes GI side effects alongside semaglutide

Semaglutide already carries the primary GI side-effect burden (nausea, gastroparesis, constipation). Stacking a second GI-toxic agent is the most common way people accidentally make themselves miserable. None of the candidates in §4 are primary GI offenders at modal doses, but this is the frame to hold if any new GI peptide is proposed.

Baseline labs should be drawn before any stack addition — this is the "were we actually at baseline" snapshot to compare against later.

• hs-CRP and ESR — every 3 months in the first year, then every 6 months if stable. Trend matters more than any single value. A creeping hs-CRP above your personal baseline is the earliest quantitative flare signal.
• CBC and CMP — baseline + every 6 months. Catches liver, kidney, hematologic issues unrelated to any specific peptide.
• IGF-1 — mandatory if any GH-class peptide (tesamorelin, ipamorelin, CJC-1295) is running. Baseline, 6–8 weeks after start, then every 3 months. Target mid-normal range for age.
• Fasting glucose / HbA1c — already standard on semaglutide; becomes more important with any GH-class peptide added.
• Serum copper / ceruloplasmin — if chronic injectable GHK-Cu. Baseline + every 6 months.
• PASI or dermatology check — annually, or earlier if skin changes. Skin status is the most visible flare channel.
• Joint symptom diary — written, dated. Morning stiffness duration, joint count, fatigue, sleep. Unfashionable and works.

Flare early-warning signs

Any of the following — treat as a stop-and-reassess signal:

• Morning stiffness duration >30 min for more than a week.
• New or worsening enthesitis (Achilles, plantar fascia, lateral epicondyle).
• Dactylitis (sausage digit).
• New or worsening psoriatic skin lesions.
• hs-CRP trending upward across two consecutive draws.
• Unexplained fatigue qualitatively different from a normal bad week.

Deliberately simple. Flares are not the moment for complex decision-making.

1. STOP the entire peptide stack (everything except semaglutide).
2. Call your rheumatologist — do not wait for a routine appointment.
3. Draw hs-CRP / ESR / CBC / CMP if not done in the last 2 weeks.
4. Follow rheumatologist guidance on resuming DMARD or biologic if indicated.
5. Do NOT restart the peptide stack until the flare resolves AND rheumatology signs off.
6. When restarting, reintroduce one peptide at a time, 4+ weeks apart, with labs between — so you can attribute any recurrence.

Semaglutide is not on this stop list: it is the baseline anti-inflammatory anchor, and the decision to continue, pause, or change it belongs to the prescribing physician — not this guide.